This company listing is no longer active
3080 Stock Overview
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Conformis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.05 |
| 52 Week High | US$3.92 |
| 52 Week Low | US$0.96 |
| Beta | 1.39 |
| 1 Month Change | 2.50% |
| 3 Month Change | 102.97% |
| 1 Year Change | n/a |
| 3 Year Change | -85.23% |
| 5 Year Change | -91.56% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3080 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -4.0% | -1.2% |
| 1Y | n/a | -3.7% | 1.2% |
Return vs Industry: Insufficient data to determine how 3080 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 3080 performed against the German Market.
Price Volatility
| 3080 volatility | |
|---|---|
| 3080 Average Weekly Movement | 24.4% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3080's share price has been volatile over the past 3 months.
Volatility Over Time: 3080's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 295 | Mark Augusti | www.conformis.com |
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation.
Conformis, Inc. Fundamentals Summary
| 3080 fundamental statistics | |
|---|---|
| Market cap | €16.49m |
| Earnings (TTM) | -€38.45m |
| Revenue (TTM) | €52.87m |
0.3x
P/S Ratio-0.4x
P/E RatioIs 3080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3080 income statement (TTM) | |
|---|---|
| Revenue | US$57.06m |
| Cost of Revenue | US$38.12m |
| Gross Profit | US$18.95m |
| Other Expenses | US$60.45m |
| Earnings | -US$41.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.27 |
| Gross Margin | 33.21% |
| Net Profit Margin | -72.73% |
| Debt/Equity Ratio | 64.4% |
How did 3080 perform over the long term?
See historical performance and comparison